eli lilly and company zepbound

Order byBest matchMost fresh

Eli Lilly, Zepbound

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

Eli Lilly and Company's Zepbound demonstrated superior weight reduction compared to Novo Nordisk's Wegovy in a 72-week head-to-head trial.

· 2d

· 2d · on MSN

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy

· 12d · on MSN

Lilly star weight-loss drug Zepbound faces coverage challenge from CVS Health

What is the most effective weight loss drug?

drug maker Eli Lilly put its own weight loss drug Zepbound against the popular drug Wegovy, and Zepbound outperformed, causing 6% more weight loss than its competitor.

· 1d

· 2d

New study compares Wegovy and Zepbound for the first time

· 2d

Study finds Zepbound may help people lose more weight than Wegovy

Hosted on MSN2d

Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary

The discontinuation rate due to side effects was 6.1% for Zepbound and 8% for Wegovy. On Stocktwits, sentiment toward Eli Lilly was ‘bearish’ despite high message volume. Some retail users speculated on the company’s price trajectory, with one ...

Zepbound trims more belly fat than Wegovy, study shows

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.

12d

CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

Reuters on MSN12d

Eli Lilly shares plunge as company downplays CVS’s move to drop Zepbound coverage

Eli Lilly said lower prices for the company’s weight-loss drug trimmed revenue in the quarter, but that demand remained strong

Yahoo Finance2d

Eli Lilly and Company (LLY)

Eli Lilly and Company (NYSE: LLY) today announced detailed results from SURMOUNT-5, a Phase 3b open-label clinical trial, evaluating the safety and efficacy of Zepbound (tirzepatide), a dual GIP ...